Antagonistic anti–TIM-1 does not interfere with GVT effect. Mice were infused IV with Luc⁺ A20 tumor cells on day 0 of BM transplantation. Tumor growth of Luc⁺ A20 cells as assessed by BLI. BALB/c recipient mice were transplanted with B6 TCD BM and Luc⁺ A20 cells (☐), Luc⁺ A20 cells and anti–TIM-1 mAb (3D10; 400 μg per mouse given IP) (▪), Tcon and Luc⁺ A20 cells (▼), or Tcon, Luc⁺ A20 cells and anti–TIM-1 mAb (3D10; 400 μg per mouse given IP) (●). (A) Representative bioluminescence images on days +7, +10, and +14 after transplantation are shown. (B) Bioluminescence signal intensity time course, pooled across 3 independent experiments with n ≥ 4 mice per group. (C-D) Tumor-free survival curve (C) and GVHD-free survival (D) of BALB/c recipient mice transplanted with B6 TCD BM and Luc⁺ A20 cells (☐), Luc⁺ A20 cells and anti–TIM-1 mAb (3D10; 400 μg per mouse given IP) (▪), Tcon and Luc⁺ A20 cells (▼), or Tcon, Luc⁺ A20 cells and anti–TIM-1 mAb (3D10; 400 μg per mouse given IP) (●). The animal from the BM plus Tcon-cell plus A20-cell group that was reported in the tumor-free survival curve was excluded from the GVHD-free survival curve. The animals that survived and are reported in panel D were tumor-free. Error bars indicate SEM. For statistical analysis, the 2-tailed Student t test was used. *P ≤ .05, ***P ≤ .001.